Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

5.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.8K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2.

Asian Pacific journal of cancer prevention : APJCP·2011
Same author

CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2011
Same author

Detailed characterization of polar compounds of residual oil in contaminated soil revealed by Fourier transform ion cyclotron resonance mass spectrometry.

Chemosphere·2011
Same author

Solid-phase microextraction coupled to LC-ESI-MS/MS: evaluation and correction for matrix-induced ionization suppression/enhancement for pharmaceutical analysis in biological and environmental samples.

Analytical chemistry·2011
Same author

Shape-persistent two-component 2D networks with atomic-size tunability.

Chemistry, an Asian journal·2011
Same author

The products of the thermal decomposition of CH3CHO.

The Journal of chemical physics·2011

Related Experiment Video

Updated: Jan 2, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

17.4K

Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma.

Xu Zhang1, Zhiguo Zhang1

  • 1Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA; Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA.

Trends in Cancer
|December 10, 2019
PubMed
Summary

Diffuse intrinsic pontine glioma (DIPG) is a deadly pediatric cancer. This review explores how K27M mutations reprogram the cancer epigenome, identifying potential therapeutic targets for DIPG treatment.

Keywords:
H3K27Mdiffuse intrinsic pontine gliomaoncohistone mutationpoised enhancers

More Related Videos

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.9K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.4K

Related Experiment Videos

Last Updated: Jan 2, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

17.4K
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.9K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.4K

Area of Science:

  • Pediatric oncology
  • Cancer epigenetics
  • Molecular biology

Background:

  • Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brain tumor.
  • Currently, no effective treatments exist for DIPG, leading to a universally fatal outcome.
  • A significant majority of DIPG cases (60-70%) are associated with specific histone H3 gene mutations (K27M).

Purpose of the Study:

  • To review the role of K27M mutations in DIPG pathogenesis.
  • To elucidate how these mutations alter the cancer epigenome.
  • To identify potential therapeutic targets and agents for DIPG.

Main Methods:

  • Literature review of studies on DIPG genetics and epigenetics.
  • Analysis of the molecular mechanisms driven by K27M mutations.
  • Identification and discussion of emerging therapeutic strategies.

Main Results:

  • K27M mutations in histone H3 are a key driver of DIPG.
  • These mutations lead to widespread epigenetic dysregulation, promoting tumorigenesis.
  • Specific molecular pathways and targets amenable to therapeutic intervention have been identified.

Conclusions:

  • Understanding the epigenetic reprogramming by K27M mutations is crucial for DIPG treatment.
  • Targeting these specific molecular alterations offers promising therapeutic avenues.
  • Further research into novel drug targets and agents is essential for improving DIPG outcomes.